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Cardiac Resynchronization
Therapy in Patients With Narrow QRS
We read with great interest the report by Achilli et al. (1) on
cardiac resynchronization therapy (CRT) in patients with heart
failure (HF) and narrow QRS: the clinical implication of those
data is huge in light of the rapidly expanding indications for CRT.
Achilli et al. (1) described the “long-term” efficacy of CRT in 52
patients (all preselected by echocardiographic recognition of inter-
and intraventricular dyssynchrony) affected by HF, 14 of them
with a QRS 120 ms. Positive results were obtained both from a
clinical and echocardiographic point of view.
The fact that the mean follow-up was 565 days, but that the
“clinical and echocardiographic results” refer to the six-month
follow-up, could be a bit confusing. This may be misleading, and
no doubt the definition of “mid-term” rather than “long-term”
would be more appropriate in describing the follow-up by Achilli
et al. (1).
Our larger experience (158 patients, mean follow-up 1 year) (2),
published just a year before Achilli et al. (1) study (and probably
overlooked by the investigators) also confirms positive results of
CRT in patients with narrow QRS. Based purely on basal QRS
duration, without preselection by any echocardiographic parame-
ter, our patients were defined as wide QRS (150 ms, 128
patients) and narrow QRS (150 ms, 30 patients, 13 with QRS
120 ms, a number comparable to the Achilli et al. [1] narrow
QRS cohort). Our data confirm that, in both groups, CRT
significantly improved clinical and echocardiographic parameters;
in our series these good results were sustained for at least one year.
The most relevant difference between Achilli et al’s. (1) and our
population concerns the mortality rate in the narrow QRS group;
in fact, the 21.4% reported by Achilli et al. (1) in patients with
narrow QRS strongly contrasted with no deaths in our series. In
addition, the mortality rate reported by the investigators was
similar in patients with both narrow and wide QRS duration,
being substantially higher than other reported series.
Finally, we agree that echocardiographic indicators of dyssyn-
chrony can be useful; nonetheless, our data on patients with narrow
QRS have clearly demonstrated that the use of pure “clinical”
selection criteria (i.e., drug refractoriness, severe HF, low ejection
fraction, large diameters) has permitted us to identify patients who
can substantially benefit from CRT in the long term.
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REPLY
We appreciate the interest of Dr. Gasparini and colleagues in our
report (1) and respond to their specific points as follows. First, as
regards our follow-up, we are of the opinion that the definition of
“long-term” is correct considering a mean observation period for
our patient population of 546 days, but clinical and echocardio-
graphic data were collected at 6 months as this reflected the
minimum follow-up for all patients and we believed that this
guaranteed a homogeneous data evaluation. Nevertheless, the
latter definition obviously reflects a “mid-term” follow-up.
Second, we agree that the data published by Gasparini et al. (2)
concur with ours in underscoring the benefit of cardiac resynchro-
nization therapy (CRT) in patients with heart failure and narrow
QRS. However, the definition of a “narrow” QRS is substantially
different in the two studies (110  10 ms vs. 133  15 ms), thus
making the confrontation between patient populations inappropri-
ate as regards the electrical asynchrony profile. Moreover, we
acknowledge with pleasure that 13 patients in the Gasparini et al.
(2) series had a QRS duration 120 ms, but this issue was not
cited in the original report.
The major difference between the two populations is in the
criteria used for the selection of patients. We required the presence
of inter- and intraventricular asynchrony documented by echocar-
diography, whereas the Gasparini et al. (2) patients were selected
solely on the basis of clinical features.
Third, the high mortality rate of our patients might be due to a
disproportionate percentage of New York Heart Association
(NYHA) functional class IV (40%) patients with respect to
previous studies and the absence of functional class II patients in
our study; this is because we had decided, at least in the initial
phase of our experience, to reserve CRT for very ill patients.
Conversely, the subgroup with a narrow QRS from the Gasparini
et al. (2) series included 40% of NYHA functional class II patients.
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Moreover, our selection criteria with respect to intraventricular
asynchrony were highly restrictive and may have led to selection of
patients with a very unfavorable prognosis.
Fourth, we agree with Dr. Gasparini and colleagues that the
screening of patients suitable for CRT based on merely clinical
criteria may be sufficient in specific settings. However, we are of
the opinion that this simplification could increase the number of
non-responders to CRT: this issue is critical, and current research
for the identification of responders is in active development. There
is evidence that left intraventricular asynchrony detected at echo-
cardiography may represent the best parameter for the identifica-
tion of responders to CRT (3,4). Therefore, we are convinced that
the selection of patients for CRT should necessarily include the
evaluation of mechanical asynchrony, the latter representing the
pathophysiologic substrate for resynchronization pacing in heart
failure patients.
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Cerebroprotection
Mediated by Angiotensin II
I read with great interest the provocative study by Fournier et al.
(1) on cerebroprotection mediated by angiotensin II. The investi-
gators state that beta-blockers are remarkably ineffective in reduc-
ing the risk of stroke; however, they cite three studies all performed
with one beta-blocker, atenolol, which has never been proven to
reduce sudden death.
In general, the results of multiple studies with one drug cannot
be interpreted as representing the class of that drug. In the case of
beta-blockers in particular, publication of the Beta-blocker Eval-
uation of Survival Trial (BEST) (2), which failed to replicate the
mortality reduction demonstrated by bisoprolol, metoprolol ex-
tended release, and carvedilol in systolic heart failure, clearly
established the fallacy of assuming a class effect for the benefit of
beta-blockers for that particular indication. Furthermore, in the
recently published Carvedilol Or Metoprolol European Trial
(COMET) (3), the stroke rate was reduced significantly (67%)
with carvedilol compared with the short-acting metoprolol tartrate
(4). Thus, the investigators need to limit their conclusion of the
ineffectiveness of beta-blockers to atenolol and avoid invoking
beta-blockers as a class in this argument.
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REPLY
Dr. Ghali raises an interesting point about our study (1) that
deserves to be scrutinized. In hypertension, beta-blockers as a class
have never been shown to reduce heart attacks or strokes (2,3). This
is true for atenolol in several prospective placebo-controlled random-
ized trials, but also for propranolol in the Medical Research Council
(MRC) study (4) and for oxprenolol in the International Prospective
Primary Prevention Study in Hypertension (IPPPSH) (5). In Cardiac
Insufficiency Bisoprolol Study (CIBIS-II), the rate of hospitalization
for a stroke was almost twice as high in the bisoprolol arm as in the
placebo arm (6). Thus, there are several prospective randomized
studies with atenolol, propranolol, oxprenolol, or bisoprolol docu-
menting that beta-blockers are not efficacious in reducing strokes.
A notable exception that Dr. Ghali mentioned is the Carvedilol
Or Metoprolol European Trial (COMET) in congestive heart
failure patients (7). However, carvedilol is a drug that is distinctly
different from traditional beta-blockers in that it does have some
alpha-blocking properties and other features that exert a more
favorable effect on systemic hemodynamic, metabolic endocrine
findings, and target organ disease than do traditional beta-blockers
(8). We also should emphasize that a stroke reduction in conges-
tive heart failure without hypertension cannot necessarily be
extrapolated to uncomplicated hypertension. Indeed, heart failure
per se is a risk factor for stroke, but the pathogenesis is different
from the one in hypertension and often involves emboli of cardiac
origin. Because carvedilol was superior to metoprolol in preventing
congestive heart failure and sudden death, it is likely that it
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